Skip to main content
letter
. 2015 Oct 23;5(10):e362. doi: 10.1038/bcj.2015.86

Figure 1.

Figure 1

Lymphocyte counts and CD4-positive T-cell counts. Box plots of lymphocyte counts (a) and CD4-positive T-cell counts (b) among patients who were treated with bendamustine with or without rituximab from baseline to 7–9 months after the completion of bendamustine.